drugset / Trial / NCT05836766

Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion

NCT05836766

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.

Timeline

Start
2023-06-05
Primary completion
2024-07
Completion
2024-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cilostazol Small molecule 25 mg Other
Comparator Dexborneol Small molecule 6 mg Other